These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12002772)

  • 1. Meningeal relapse after double peripheral blood stem cell transplantation in IgD myeloma.
    Ochiai N; Shimazaki C; Okano A; Hatsuse M; Takahashi R; Hirai H; Ashihara E; Inaba T; Fujita N; Nakagawa M
    Leuk Lymphoma; 2002 Mar; 43(3):641-3. PubMed ID: 12002772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multiple myeloma of the IgD-lambda type invading CNS].
    Kitamura K; Takeuchi J; Kanbe E; Oka H; Saiki M; Aikawa S; Kura Y; Hatta Y; Yamazaki T; Ito T; Sawada U; Horie T
    Rinsho Ketsueki; 2004 Oct; 45(10):1124-8. PubMed ID: 15553049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rapidly progressive AL amyloidosis in a patient with relapsed multiple myeloma after achieving a complete response to tandem autologous PBSCT].
    Yagi H; Ozaki S; Sekimoto E; Shibata H; Shigekiyo T; Satake N
    Rinsho Ketsueki; 2013 Dec; 54(12):2171-6. PubMed ID: 24452148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Light chain escape followed by leukemic transformation in a patient with IgD myeloma].
    Hatsuse M; Fuchida S; Okano A; Murakami S; Shimazaki C
    Rinsho Ketsueki; 2015 Jan; 56(1):48-50. PubMed ID: 25745970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningeal involvement in multiple myeloma: report of a case with cytologic and immunocytochemical diagnosis.
    Cavanna L; Invernizzi R; Berte' R; Vallisa D; Buscarini L
    Acta Cytol; 1996; 40(3):571-5. PubMed ID: 8669198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure.
    Rebibou JM; Caillot D; Casasnovas RO; Tanter Y; Maillard N; Solary E; Rifle G; Guy H
    Bone Marrow Transplant; 1997 Jul; 20(1):63-5. PubMed ID: 9232259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
    Fenk R; Liese V; Neubauer F; Bruns I; Kondakci M; Balleisen S; Saure C; Schröder T; Haas R; Kobbe G
    Leuk Lymphoma; 2011 Aug; 52(8):1455-62. PubMed ID: 21657961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
    Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
    Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
    Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningeal Myelomatosis.
    DeFilipp Z; Sahovic EA; Nooka AK
    J Oncol Pract; 2016 Feb; 12(2):187-8. PubMed ID: 26869657
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Morris C; Iacobelli S; Gahrton G; van Biezen A; Drake M; Garderet L; Potter M; Schattenberg AV; Cornelissen JJ; Hamladji RM; Martelli M; Petersen E; Rovira M; Bandini G; Kroger N; de Witte T
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1054-8. PubMed ID: 25708221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression.
    Somers LJ; Shaw B; Lyn BE; McMillan AM; Mahendra P
    Clin Lab Haematol; 1998 Jun; 20(3):189-90. PubMed ID: 9681237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [IgD myeloma with skin tumor].
    Kawakami K; Ishiyama T; Onizuka T; Hino K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1994 Nov; 35(11):1305-9. PubMed ID: 7823397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
    Chong YP; Kim S; Ko OB; Koo JE; Lee D; Park SH; Park SJ; Lee D; Kim SW; Suh C
    J Korean Med Sci; 2008 Oct; 23(5):819-24. PubMed ID: 18955788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.